Associated Papers
Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S et al.
American Journal of Hematology, 2012
P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia.
Cang S et al.
Journal of Hematology & Oncology, 2008
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.
Cortes J et al.
Blood, 2007
Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors.
von Bubnoff N et al.
Cancer Research, 2003
Select a paper to view details